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Introduction
Bisphosphonates were designed as synthetic analogues
of endogenous pyrophosphate, which act as a regulator
of bone metabolism and is found abundantly in bone
matrix [1,2]. Non-nitrogen containing first-generation
bisphosphonates, such as clodronate or etidronate,
which closely resemble pyrophosphate, primarily
induce osteoclast apoptosis by intracellular accumula-
tion of non-hydrolyzable ATP analogues [3]. Nitrogen-
containing bisphosphonates, such as zoledronate,
pamidronate, ibandronate and alendronate, have been
found to act on bone-resorbing osteoclasts by inhibit-
ing farnesyldiphosphate (FPP) synthase, a key regula-
tory enzyme in the mevalonate pathway. Inhibition of
FPP synthase prevents post-translational prenylation
of small GTPases, causing impaired osteoclast function
and sensitizing cells for apoptosis [4–6].
To date, zoledronate is one of the most potent
bisphosphonates with very high affinity to bone [7].
It is in widespread use for the treatment of patients
with multiple myeloma or bone metastasis due to solid
tumours as well as hypercalcaemia of malignancy [8].
Zoledronate has been associated both with dose-
dependent and infusion time-dependent acute and
chronic renal failure [2,9–15]. Markowitz et al. [9]
described six patients suffering from underlying multi-
ple myeloma or Paget’s disease, who developed
zoledronate-associated toxic acute tubular necrosis
(ATN). The predominant renal biopsy findings in
these patients were marked tubular degenerative
changes. While all biopsies displayed some degree of
global glomerular sclerosis, no one exhibited lesions of
focal segmental glomerulosclerosis (FSGS) or its
morphological variant collapsing glomerulopathy.
Both FSGS and its variant collapsing glomerulopathy
have been described following treatment with pami-
dronate [2,16–19] and other drugs, e.g. lithium,
interferon-a or heroin [20]. FSGS has also been
reported to be associated with viral infections [21],
most importantly with HIV [21,22], hepatitis C and
parvovirus B19 [23]. Malignant arterial hypertension
and hereditary conditions [20] have also been reported
to be associated with FSGS. To our knowledge, no
patients with collapsing FSGS and nephrotic syndrome
associated with zoledronate have so far been described
in the literature.
Case
Sixteen months prior to the current admission, a
65-year-old Caucasian male patient with a history
of arterial hypertension, treated with amlodipin
10mg/day, was evaluated because of lytic vertebral
bone fractures. A bone marrow aspirate showed
30% plasma cells and multiple myeloma IgG-k
(Durie-Salmon stadium IIIA) was diagnosed.
12 months before the actual hospitalization, the
fourth cycle of chemotherapy with vincristine, adri-
blastin and dexamethasone (VAD) was completed. Ten
months before admission, autologous stem cell trans-
plantation was performed after induction chemother-
apy with melphalan, because of 50% bone marrow
plasma cell infiltration. Another 4 months later, a
second autologous stem cell transplantation was done
after induction chemotherapy with melphalan, because
of persistent bone marrow plasma cell infiltration
(5–10%). Two days before admission, a routinely
performed bone marrow aspirate showed formal
histological remission but remaining atypical plasma
cells (<5%).
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A therapy with standard dose zoledronate
(4mg over 15min) was administered beginning
16 months before the actual hospitalization, for a
total of 10 infusions (Figure 1). Because of an elevated
plasma creatinine (2.39mg/dl (211mmol/l)) 2 weeks
after the 9th application, the last dose of zoledronic
acid was reduced to 3.3mg.
At admission, the patient presented with elevated
plasma creatinine (4.6mg/dl (410 mmol/l)), heavy
proteinuria (protein/creatinine ratio 1731mg/mmol),
hypoalbuminaemia (15 g/l), oedema and hypercholes-
terolaemia (6.6mmol/l). Acute renal failure with
nephrotic syndrome was diagnosed.
Sonography showed normal-sized kidneys without
signs of obstruction or mass lesions. Duplex studies of
the renal arteries and veins revealed no abnormalities.
Serological evaluations for HIV, hepatitis C or
hepatitis B virus and parvovirus B19 were negative.
A renal biopsy was investigated by light and electron
microscopy as well as immunohistochemistry
(Figures 2 and 3). By light microscopy, 12 glomeruli
were seen. Two of them were completely obsolescent
and five showed perihilar or peripheral segmental
sclerosis, with additional hyalinosis and synechia
formation in two of them. In one glomerulus, modest
protein storage was present in podocytes and in
another one there was low-level activation and crowd-
ing of the podocytes overlying slightly collapsed loops.
Immunohistochemistry showed massive focal and
segmental deposits of IgM and complement factors
(C1q, C3, C4, C5b-9) in glomeruli with segmental
lesions. All other immunoglobulins were absent.
Electron microscopy confirmed segmental sclerosis,
mild collapse and activation of podocytes and hyali-
nosis. Complete foot process fusion was present in the
less severely affected glomerular segments. The arteri-
oles showed severe circular hyalinosis and were
positive by immunohistochemistry for IgM, comple-
ment C3 and C5b-9.
In the tubulo-interstitial space mild diffuse fibrosis,
accompanied by scattered infiltration of lymphocytes
and histiocytes was present. The tubules showed early
signs of atrophy in some areas or luminal dilatation
with epithelial cell damage of variable degree: irregular
vacuolization, loss of brush border, irregular nuclear
distribution and increased mitotic activity (Figure 3).
Besides tubular injury, these pathological findings were
consistent with FSGS and its collapsing variant.
Importantly, there was no evidence of amyloidosis or
light chain deposition disease.
Because of rapid decline in renal function, haemo-
dialysis was started 10 days after admission. During
the following 10 weeks, no improvement of renal
function could be observed.
Discussion
To our knowledge, we report the first patient present-
ing with collapsing FSGS, nephrotic syndrome
and concomitant renal failure associated with the
administration of zoledronate. So far, 80 patients
have been described with renal failure associated
with the administration of zoledronate [2,9,12–15].
The time from drug initiation to diagnosis of renal
failure varied from days [12,15] to 9 months [9,12].
In all available cases, histopathology showed ATN
and it was speculated that the pathogenesis may be
similar to the effects of bisphosphonates observed in
osteoclasts [9].
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Fig. 1. Time course of zoledronate-associated acute renal failure with nephrotic syndrome. Connected filled diamonds represent
plasma creatinine concentration; Shaded columns represent urine protein/creatinine ratio in mg/mmol (numbers above the columns
indicate the ratio) and cylinders represent urine kappa light chain/creatinine ratio (values between 3 and 12mg/mmol). HD, haemodialysis;
VAD, vincristine, adriblastin, dexamethason. To convert creatinine from mmol/l to mg/dl divide by 88.4.
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Fig. 2. (A) Glomerular segmental sclerosis with slightly collapsed loops and podocyte crowding in Bowman’s space. Note medium severe
arteriolar hyalinosis of the afferent arteriole (PAS stain, 400). (B) Segmental sclerosis and hyalinosis with large nodular protein deposits in
peripheral loops (red), synechia formation with Bowman’s capsule and slight activation of podocytes (trichrome stain, 400). (C) Lumpy
deposits of IgM in peripheral capillary loops, severe staining of peripheral capillaries and nodular deposits in the afferent arteriole
(IgM immunohistochemistry in paraffin section, 400). (D) Completely obsolescent glomerular segment, with denuded basement membranes
and activated podocytes in Bowman’s space (EM, 2800).
Fig. 3. (A) Tubulo-interstitial space with partly atrophic, partly dilated tubules and scattered interstitial inflammatory cells. Note irregular
cell lining in tubules (HE stain, 200). (B) Interstitial fibrosis and tubules with early signs of atrophy (trichrome stain, 200).
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In our patient, plasma creatinine values rose rapidly
15 months after initiation of zoledronate (Figure 1).
The dose of zoledronate was reduced from 4mg to
3.3mg for the last infusion after detection of declining
renal function. Nevertheless, the patient developed
rapid progressive renal failure, finally requiring
haemodialysis.
Infection with HIV, hepatitis B or hepatitis C and
parvovirus B19 could be excluded. Taking
into account the decline of renal function with
appearance of nephrotic syndrome within one
month and the discussed histopathological features,
hypertensive nephropathy was considered an improb-
able cause for the FSGS. Considering the persistent
light chain proteinuria on admission, residual multiple
myeloma might explain some of the clinical
and histopathological findings. However, lacking
evidence of amyloid, IgG-k and electron dense
deposits, excluded the diagnosis of amyloidosis
or light chain deposition disease. Bisphosphonate-
associated nephrotic syndrome with accompanying
renal failure portends a poor prognosis. Only
about 20% of such patients will experience any
degree of recovery and almost half of them need
haemodialysis [18].
Currently, all pathological subsets of FSGS
are believed to be associated with podocyte dysfunc-
tion. Histopathological features include change
of normal appearance, plasma vacuolization,
hyperplasia and hypertrophy, foot process fusion as
well as loss of podocytes [19,20,24,25]. Podocyte
dysregulation and cell cycle derangements, leading
to de-differentiation and apoptosis, have been
implicated in the pathophysiology of FSGS
[19,20,25,26]. Pamidronate has been shown to be
associated with FSGS [2,16–19]. Barri et al. [17]
reported five cases of FSGS, including one with
collapsing glomerulopathy, associated with the
administration of pamidronate. All patients showed
variable podocyte injury and extensive foot process
effacement.
Similar to zoledronate, ATN has been reported
following treatment with pamidronate [2].
Interestingly, the question why pamidronate or
zoledronate-associated renal toxicity involves differ-
ent targets (e.g. tubular cells, podocytes) remains
unresolved. It is believed that different dosage
regimens and individual susceptibility to renal disease
may play a role [17]. Whether inhibition of prenyla-
tion of GPTases due to nitrogen-containing
bisphosphonates may play a role in podocyte injury
is currently unknown, but it is intriguing to speculate
that similar mechanisms may be responsible
for podocyte as well as osteoclast dysfunction and
apoptosis.
In conclusion, we report the first case of
zoledronate-associated renal failure with FSGS and
nephrotic syndrome. So far, only ATN has been
associated in the literature with therapy of zoledronate.
Therefore, we believe that it is important to monitor
not only creatinine values but also proteinuria for
earlier detection of worsening renal function in patients
treated with zoledronate.
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